Efficacy of Allopurinol in Cardiovascular Diseases: A Systematic Review and Meta-Analysis by Ullah, Waqas et al.
Thomas Jefferson University 
Jefferson Digital Commons 
Abington Jefferson Health Papers Abington Jefferson Health 
6-3-2020 
Efficacy of Allopurinol in Cardiovascular Diseases: A Systematic 
Review and Meta-Analysis 
Waqas Ullah 
Abington Jefferson Health 
Shristi Khanal 
Abington Jefferson Health 
Rozi Khan 
Medstar Union Memorial Hospital 
Bikash Basyal 
Abington Jefferson Health 
Samavia Munir 
Abington Jefferson Health 
See next page for additional authors 
Follow this and additional works at: https://jdc.jefferson.edu/abingtonfp 
 Part of the Internal Medicine Commons 
Let us know how access to this document benefits you 
Recommended Citation 
Ullah, Waqas; Khanal, Shristi; Khan, Rozi; Basyal, Bikash; Munir, Samavia; Minalyan, Artem; 
Alraies, M. Chadi; and Fischman, David L., "Efficacy of Allopurinol in Cardiovascular Diseases: A 
Systematic Review and Meta-Analysis" (2020). Abington Jefferson Health Papers. Paper 25. 
https://jdc.jefferson.edu/abingtonfp/25 
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital 
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is 
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections 
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested 
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been 
accepted for inclusion in Abington Jefferson Health Papers by an authorized administrator of the Jefferson Digital 
Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu. 
Authors 
Waqas Ullah, Shristi Khanal, Rozi Khan, Bikash Basyal, Samavia Munir, Artem Minalyan, M. Chadi Alraies, 
and David L. Fischman 
This article is available at Jefferson Digital Commons: https://jdc.jefferson.edu/abingtonfp/25 
Articles © The authors   |   Journal compilation © Cardiol Res and Elmer Press Inc™   |   www.cardiologyres.org
This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits 
unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited
226
Original Article Cardiol Res. 2020;11(4):226-232
Efficacy of Allopurinol in Cardiovascular Diseases: A 
Systematic Review and Meta-Analysis
Waqas Ullaha, e, Shristi Khanala, Rozi Khanb, Bikash Basyala, Samavia Munira, 
 Artem Minalyana, M. Chadi Alraiesc, David L. Fischmand
Abstract
Background: Given current evidence, the use of allopurinol for the 
prevention of major cardiovascular events (acute cardiovascular syn-
drome (ACS) or cardiovascular mortality) in patients undergoing cor-
onary artery bypass graft (CABG), after index ACS or heart failure 
remains unknown.
Methods: Multiple databases were queried to identify studies com-
paring the efficacy of allopurinol in patients undergoing CABG, after 
ACS or heart failure. The unadjusted odds ratio (OR) was calculated 
using a random effect model.
Results: A total of nine studies comprising 850 patients (allopurinol 
480, control 370) were identified. The pooled OR of periprocedural 
ACS (OR: 0.25, 95% confidence interval (CI): 0.06 - 0.96, P = 0.05) 
and cardiovascular mortality (OR: 0.22, 95% CI: 0.07 - 0.71, P = 
0.01) was significantly lower in patients receiving allopurinol during 
CABG compared to patients in the control group. The overall number 
needed to treat (NNT) to prevent one ACS event was 11 (95% CI: 7 - 
28), while the NNT to prevent one death was 24 (95% CI: 13 - 247). 
By contrast, the odds of cardiovascular mortality in the allopurinol 
group were not significantly different from the control group in pa-
tients on long-term allopurinol after ACS or heart failure (OR: 0.33, 
95% CI: 0.01 - 8.21, P = 0.50) and (OR: 1.12, 95% CI: 0.39 - 3.20, P 
= 0.83), respectively. Similarly, the use of allopurinol did not reduce 
the odds of recurrent ACS events at 2 years (OR: 0.32, 95% CI: 0.03 
- 3.18, P = 0.33).
Conclusions: Periprocedural use of allopurinol might be associated 
with a significant reduction in the odds of ACS and cardiovascular 
mortality in patients undergoing CABG. Allopurinol, however, offers 
no long-term benefits in terms of secondary prevention of ACS or 
mortality. Larger scale studies are needed to validate our findings.
Keywords: Allopurinol; ACS; CABG; Heart failure
Introduction
Approximately 50% of patients undergoing coronary artery 
bypass graft (CABG) surgery have periprocedural reperfu-
sion injury resulting in a considerable depression of the early 
postsurgical cardiac function (myocardial stunning) [1]. Post-
CABG myocardial stunning was widely held to result from un-
controlled free radical activity and thought to be amenable to 
anti-free radical therapy [2]. Given this, almost half the CABG 
patients theoretically could benefit from the administration of 
free oxygen radical scavengers. However, some clinical stud-
ies have failed to demonstrate convincing evidence on the pro-
duction of free radicals during revascularization procedures. 
The addition of locally active agents (anti-free radical) to the 
cardioplegic solutions (used during the CABG procedure) has 
yielded disappointing clinical outcomes [3, 4].
Several studies had found an increased level of systemic free 
radical activity during and after CABG procedures when the 
antioxidant defense mechanism of myocardium was thought to 
be considerably impaired [3, 5]. It is, therefore, reasonable to 
speculate that circulating free radical toxins when antioxidant 
defenses are decreased produce myocardial stunning [5]. This 
hypothesis provides a logical background for the limited, yet 
controversial clinical benefits associated with the systemic ad-
ministration of direct free radical scavenging agents such as al-
lopurinol at times of myocardial ischemia [6, 7].
The proposed mechanisms of allopurinol include systemic 
reduction of free radical activity by inhibition of the xanthine oxi-
dase (a superoxide-generating enzyme), suppressing the secretion 
of inflammatory mediators and increasing nitric oxide production 
[8]. The later could also potentially reduce the incidence of acute 
coronary syndrome (ACS), as was suggested by Huang et al [9]. 
These theoretical benefits have led to studies examining the uti-
lization of allopurinol before CABG and for the secondary pre-
vention of ACS. However, evidence of its efficacy is scarce and 
controversial. Our study aims to bring consensus on the clinical 
use of allopurinol in patients undergoing CABG or after an ACS.
Materials and Methods
A structured literature search of electronic databases, including 
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MEDLINE (PubMed, Ovid), EMBASE, clinicaltrials.gov, and 
Cochrane, was performed using a combination of keywords 
and medical subject headings (MeSH). The keyword “allopu-
rinol” was combined with a list of MeSH terms including “is-
chemic heart disease,” “CAD,” “stable angina,” “myocardial 
infarction,” “coronary artery disease,” “MI,” “heart failure,” 
and “STEMI.” Databases were last accessed on March 2, 
2019. Based on our research question, articles from the refer-
ence lists relevant to the clinical question were also screened 
by an independent author (backward snowballing). All studies 
enrolling patients age greater than 18 years and reporting the 
role of allopurinol during CABG, post-ACS or in heart failure 
were included. The primary efficacy endpoint was MI and car-
diovascular mortality.
The statistical analysis was performed using the Cochran-
Mantel-Haenszel test under the random effect model to cal-
culate pooled odds ratio (OR) for the endpoints. The esti-
mated effect size was reported as a point estimate and 95% 
confidence interval (CI). An alpha criterion of P value less 
than 0.05 was considered statistically significant. If the eli-
gibility of a study was dubious or influencing due to its large 
sample size, a sensitivity analysis was performed. Higgins 
I-squared (I2) statistic model was used to evaluate variations 
in outcomes of included studies. I2 values of 50% or less 
corresponded to low to moderate, and 75% or higher indi-
cated large amounts of heterogeneity. The publication bias 
was illustrated graphically with funnel plotting. All statistical 
analysis was performed using the Cochrane Review Manager 
version 5.3.
Quality assessment of the included studies
The methodological quality was performed by screening all 
included articles for five different types of bias (selection, per-
formance, detection, attrition, and reporting bias). The overall 
quality of the included studies was high (Fig. 1). All included 
clinical trials were randomized minimizing the risk of selec-
tion bias. Similarly, due to appropriate “allocation conceal-
ment” across most studies, the risk of sampling bias was low. 
Rashid et al [10] failed to obtain allocation concealment and in 
the study by Goicoechea et al [8], more than 10% of patients 
were lost at follow-up, introducing some risk of selection and 
attrition bias, respectively. Reporting bias across all studies 
was reduced due to an adequate description of the study re-
sults. Similarly, the risk of detection and performance bias was 
minimal. The individual study and overall bias summaries are 
reported in Figures 1 and 2.
Results
A systematic search of the literature identified 1,371 articles. 
Following the removal of irrelevant and duplicate items, 80 
articles were deemed relevant for full text review. We further 
excluded 71 articles based on selection criteria; nine clinical 
trials qualified for final analysis (Table 1) [6, 8-15]. All includ-
ed trials enrolled patients undergoing CABG or having ACS 
or heart failure. The preferred reporting items for systematic 
reviews and meta-analyses (PRISMA) flow diagram is shown 
in Figure 3.
A total of 850 patients were included; 480 in the allopu-
rinol and 370 in the placebo or control group. The mean age 
was 63.4 years, comprising 79% male patients. Of the total 
population, 84% of patients had a history of hypertension and 
32% had diabetes mellitus. There was no significant differ-
ence in the baseline characteristics of the two groups across 
most of the studies. A significant amount of heterogeneity was 
observed in the selection criteria and follow-up durations of 
the included studies. Six of the included studies compared the 
utility of allopurinol in CABG patients, two trials studied the 
efficacy of allopurinol in the secondary prevention of ACS and 
one randomized controlled trial (RCT) studied the effect of al-
lopurinol on heart failure-related hospitalizations. Huang et al 
[9] included patients after an acute event of ACS, while Goi-
coechea et al [8] recruited patients with chronic kidney disease 
(CKD). The follow-up period in patients undergoing CABG 
was up to 30 days post-procedure, while it was 2 years in stud-
ies on ACS and 24 weeks in the study on heart failure patients. 
The daily dose of allopurinol ranged from 100 mg daily (for 
CKD patients in Goicoechea’s study) to 600 mg daily or 300 
mg twice a day. The detailed baseline characteristics are given 
in Table 1 [6, 8-15].
Allopurinol for periprocedural in CABG patients
Five studies comprising 215 patients (allopurinol 106, control 
109) contributed to this comparison. Patients receiving allopu-
rinol during the CABG procedure had significantly lower odds 
Figure 1. Summary of the methodological quality of the included studies showing minimal risk of bias (red).
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of periprocedural ACS events by 75% compared to patients on 
placebo or no medication (OR: 0.25, 95% CI: 0.06 - 0.96, P = 
0.05) (Fig. 1). On Higgin’s equation, there was no heterogene-
ity in the outcomes of the included studies (I2 = 0%) (Fig. 2). 
The study by Johnson et al [6] also showed that allopurinol 
could significantly decrease the odds of periprocedural cardio-
vascular mortality (OR: 0.22, 95% CI: 0.07 - 0.71, P = 0.01) 
(Fig. 4).
A sensitivity analysis of periprocedural CABG-related 
ACS events based on the exclusion of the study by Rashid et 
al [10] showed no significant difference between two groups 
(OR: 0.37, 95% CI: 0.10 - 1.32, P = 0.13). This indicates that 
although all studies showed a numerical advantage of lower 
ACS events in the allopurinol group, the statistically beneficial 
findings were actually driven by one study.
Allopurinol for secondary prevention
The odds of cardiovascular mortality (OR: 0.33, 95% CI: 0.01 
- 8.21, P = 0.50) or recurrent ACS events (OR: 0.32, 95% CI: 
0.03 - 3.18, P = 0.33) in the allopurinol group were not signifi-
cantly different from the control group. Similarly, in patients 
with a diagnosed heart failure, the use of allopurinol for 24 
weeks offered no benefits in terms of lower ACS events (OR: 
1.12, 95% CI: 0.39 - 3.20, P = 0.83) (Fig. 5).
Publication bias
The funnel plot showed asymmetry, indicating the possibility 
of publication bias. One study has shown the graphical viola-
tion of the midline, as depicted in Figure 6. One can argue 
that it is difficult to differentiate between “findings by chance” 
and “real asymmetry,” as only six articles were assessed for 
potential publication bias. As pointed by Sterne et al in a study 
of fewer than 10 articles, it is difficult to differentiate between 
real asymmetry and findings merely by chance [16].
Discussion
Our results revealed that prophylactic use of allopurinol in pa-
tients undergoing CABG could potentially decrease periproce-
dural MI and cardiovascular mortality. These findings, how-
ever, should be interpreted with caution, given that they were 
driven only by one study (Rashid et al) [10]. On sensitivity 
analysis, there was no significant difference in the periproce-
dural MI event rate between patients receiving allopurinol and 
those on the placebo. Similarly, Johnson et al was the only 
study to demonstrate a significantly lower rate of periproce-
dural mortality in CABG patients on allopurinol [6]. Other 
studies compared the long-term efficacy of allopurinol in pa-
tients with CKD, ACS and congestive heart failure (CHF). 
The risk of recurrent MI and cardiovascular mortality at an ex-
tended follow-up duration of 2 years was found to be identical 
between patients in allopurinol and control groups [8, 9, 11].
On review, we found a significant amount of heteroge-
neity in the inclusion criteria and outcomes of the included 
studies. Gimpel et al recruited 22 CABG patients (control 14, 
allopurinol eight) to determine the possibility of myocardial 
protection against reperfusion injury by allopurinol [14]. On 
a multivariate analysis adjusted for potential effect modifiers, 
there was no difference recorded between the two groups. This 
study, however, was designed to calculate the effect of the in-
flammatory markers (leukotrienes), and was underpowered to 
gauge the hard clinical outcomes (MI and mortality). By con-
trast, Rashid et al included 90 CABG patients, half of which (n 
= 45) received a loading dose of allopurinol in the periopera-
tive period. Compared to the control arm, allopurinol had an 
18% lower risk of perioperative MI. This numerical difference, 
however, did not reach the level of statistical significance [10].
Taggart et al randomized 20 patients to receive allopuri-
nol or to act as controls [12]. The primary endpoint measured 
was the efficacy of myocardial protection determined by serial 
Figure 2. Detailed methodological quality assessment of the included 
studies showing minimal risk of bias (red).
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measurement of high sensitive cardiac troponin T (cTnT), cre-
atine kinase (CK)-MB and myoglobin. This study also demon-
strated no significant difference in the levels of pre- and post-
operative cardiac biomarkers or electrocardiogram (ECG) (no 
evidence of perioperative infarction) at 1, 6, 24, and 72 h after 
CABG procedure [12]. Coghlan et al subsequently showed 
that compared to the control group, allopurinol pretreatment in 
CABG patients could significantly reduce the use of inotropic 
support (n = 5/25 vs. 13/25, P ≤ 0.01) and can increase the car-
diac index (P ≤ 0.004) after the surgery [13]. These differences, 
however, did not translate into the clinical outcomes. Similar 
to the study of Taggart et al [12], an identical periprocedural 
MI rate was observed between the two groups [13]. Unfortu-
nately, the comparison groups in all these studies were far from 
homogeneous, and the procedures performed were by different 
surgeons. Similarly, the duration of an ischemic event, degree 
of myocardial impairment and number of diseased coronary 
vessels were not consistent.
Johnson et al hurdled these limitations by recruiting 169 
patients (allopurinol 89, placebo 80), matched for their surgi-
cal risk factors and baseline comorbidities [6]. Contrary to pre-
vious studies, the in-hospital mortality rate in the allopurinol 
group (n = 4/89, 4%) was significantly lower than the placebo 
group (n = 14/80, 18%, P = 0.014). Similarly, cardiac perfor-
mance, scored by cardiac index and the need for mechanical 
and inotropic support, significantly favored the allopurinol 
group [6].
Three studies compared the utility of allopurinol for the 
secondary prevention of ACS and cardiovascular mortality. 
Huang et al recruited 100 patients (50 in each group) with the 
diagnosis of the ACS. At 1 month, the total effective rate of 
angina pectoris and ECG in the allopurinol group patients was 
93% and 96%, significantly better than the placebo arm (76% 
and 82%), respectively. The number of patients with stent im-
plantation and cardiovascular mortality was not significantly 
different between the two groups at 2 years [9]. Givertz et al 
randomized 253 patients with symptomatic heart failure (ejec-
tion fraction less than 40%) into allopurinol and a placebo 
group [11]. At 24 weeks, there was no significant difference in 
the clinical status of cardiomyopathy and ejection fraction be-
tween the allopurinol- and placebo-treated patients. The num-
ber of MI events was also identical between the two groups. 
This study could not exclude the possibility that a study on 
higher dose of allopurinol or long-term follow-up of a more 
homogeneous group of high-risk patients would have demon-
strated significant reductions in heart failure-related mortality 
[11]. In the RCT by Goicoechea et al, 113 patients (allopurinol 
57, control 56) with CKD (estimated glomerular filtration rate 
(eGFR) < 60 mL/min) were included [8]. Allopurinol treat-
ment slowed down kidney disease progression but showed 
no significant difference in the 2-year rate of cardiovascular 
mortality. Other notable cardiovascular events in the allopuri-
nol and control groups included heart failure in eight patients, 
ischemic coronary events, cerebrovascular accidents, periph-
eral arteriopathy, and arrhythmias in seven, five, one and one 
patients, respectively [8].
The present study systematically stratified patients based 
on their patient’s inclusion criteria and follow-up duration. 
Briefly, allopurinol confers advantages over placebo if used 
in conjunction with cardioplegic therapy during the CABG 
Figure 3. PRISMA flow diagram of the included studies. PRISMA: pre-
ferred reporting items for systematic reviews and meta-analyses.
Figure 4. Forest plot of CABG patients showing significantly lower odds of periprocedural myocardial infarction in the allopurinol 
group compared to the control group. CABG: coronary artery bypass graft.
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procedure. Our study demonstrates that periprocedural MI and 
cardiovascular mortality might be substantially lower with the 
use of anti-free radical therapy. The long-term benefits of al-
lopurinol could not be established in patients with a prior his-
tory of ACS, CKD, or heart failure.
Limitations
This meta-analysis was constrained by the limitations of the 
included studies. Only seven underpowered studies were in-
cluded in the final analysis, indicating that our overall results 
were only modest in its statistical power. This, in addition to 
the vast heterogeneity of the inclusion criteria, calls for caution 
when interpreting the results of this meta-analysis. Patient-
level data were missing to determine the impact of baseline 
comorbidities on the overall clinical outcomes. The dose-re-
sponse relationship and subgroup analysis based on the treat-
ment vs. “intention-to-treat” group was lacking in most of the 
included studies, limiting our ability to calculate their predic-
tive effects. Similarly, we could not account for the differential 
use of other prophylactic medications (in cases of CABG) or 
secondary preventive therapy (in post-ACS) patients between 
the two groups. All studies primarily focused on the biochemi-
cal outcomes, while hard clinical endpoints (mortality and MI) 
were recorded as secondary outcomes, potentially underpow-
ering the overall results. The net clinical benefit of allopurinol 
could not be ascertained as a significant amount of allopurinol-
induced complications such as renal and liver failure were ne-
glected. This can potentially reduce the precision of our esti-
mated results.
Conclusions
Allopurinol might potentially reduce the periprocedural ad-
verse events, including MI and mortality in patients undergo-
ing CABG. However, it has no long-term benefits in terms of 
Figure 5. Forest plot showing lower CABG related mortality and an identical odds of cardiovascular mortality in the allopurinol 
group compared to the control group in patients with heart failure, CKD and after PCI. CABG: coronary artery bypass graft; CKD: 
chronic kidney disease; PCI: percutaneous coronary intervention; 95% CI: 95% confidence interval.
Figure 6. Funnel plot showing a possibility of publication bias or find-
ings merely by chance.
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secondary prevention of ACS and mortality in patients with 
ACS, heart failure, or CKD. Larger scale studies are needed 
to determine the true merits of allopurinol in cardiovascular 
disease.
Acknowledgments
We sincerely thank Dr. Margot Boigon, Dr. David Smith and 
Dr. Richard Eisenstaedt for providing research opportunities 








Waqas Ullah: conceptualization, writing of the original draft, 
analysis, validation and visualization; Artem Minalyan: litera-
ture search; M. Chadi Alraies: critical review; Shristi Khanal: 
investigation; Rozi Khan: writing discussion; Bikash Basyal: 
data extraction; Samavia Munir: data extraction; David L. Fis-
chman: supervision, review and editing.
Data Availability
Any inquiries regarding supporting data availability of this 
study should be directed to the corresponding author.
References
1. Bolli R, Hartley CJ, Chelly JE, Patel BS, Rabinovitz RS, 
Jeroudi MO, Roberts R, et al. An accurate, nontraumatic 
ultrasonic method to monitor myocardial wall thickening 
in patients undergoing cardiac surgery. J Am Coll Car-
diol. 1990;15(5):1055-1065.
2. Bolli R, McCay PB. Use of spin traps in intact animals 
undergoing myocardial ischemia/reperfusion: a new ap-
proach to assessing the role of oxygen radicals in myo-
cardial "stunning". Free Radic Res Commun. 1990;9(3-
6):169-180.
3. Davies SW, Underwood SM, Wickens DG, Feneck RO, 
Dormandy TL, Walesby RK. Systemic pattern of free 
radical generation during coronary bypass surgery. Br 
Heart J. 1990;64(4):236-240.
4. Ferreira R, Llesuy S, Milei J, Scordo D, Hourquebie H, 
Molteni L, de Palma C, et al. Assessment of myocardial 
oxidative stress in patients after myocardial revasculari-
zation. Am Heart J. 1988;115(2):307-312.
5. Cavarocchi NC, England MD, O'Brien JF, Solis E, Russo 
P, Schaff HV, Orszulak TA, et al. Superoxide generation 
during cardiopulmonary bypass: is there a role for vita-
min E? J Surg Res. 1986;40(6):519-527.
6. Johnson WD, Kayser KL, Brenowitz JB, Saedi SF. A ran-
domized controlled trial of allopurinol in coronary bypass 
surgery. Am Heart J. 1991;121(1 Pt 1):20-24.
7. Tabayashi K, Suzuki Y, Nagamine S, Ito Y, Sekino 
Y, Mohri H. A clinical trial of allopurinol (Zyloric) 
for myocardial protection. J Thorac Cardiovasc Surg. 
1991;101(4):713-718.
8. Goicoechea M, Garcia de Vinuesa S, Verdalles U, Verde 
E, Macias N, Santos A, Perez de Jose A, et al. Allopurinol 
and progression of CKD and cardiovascular events: long-
term follow-up of a randomized clinical trial. Am J Kid-
ney Dis. 2015;65(4):543-549.
9. Huang Y, Zhang C, Xu Z, Shen J, Zhang X, Du H, Zhang 
K, et al. Clinical Study on efficacy of allopurinol in pa-
tients with acute coronary syndrome and its functional 
mechanism. Hellenic J Cardiol. 2017;58(5):360-365.
10. Rashid MA, William-Olsson G. Influence of allopurinol 
on cardiac complications in open heart operations. Ann 
Thorac Surg. 1991;52(1):127-130.
11. Givertz MM, Anstrom KJ, Redfield MM, Deswal A, 
Haddad H, Butler J, Tang WH, et al. Effects of xanthine 
oxidase inhibition in hyperuricemic heart failure pa-
tients: the xanthine oxidase inhibition for hyperuricemic 
heart failure patients (EXACT-HF) Study. Circulation. 
2015;131(20):1763-1771.
12. Taggart DP, Young V, Hooper J, Kemp M, Walesby R, 
Magee P, Wright JE. Lack of cardioprotective efficacy 
of allopurinol in coronary artery surgery. Br Heart J. 
1994;71(2):177-181.
13. Coghlan JG, Flitter WD, Clutton SM, Panda R, Daly R, 
Wright G, Ilsley CD, et al. Allopurinol pretreatment im-
proves postoperative recovery and reduces lipid peroxida-
tion in patients undergoing coronary artery bypass graft-
ing. J Thorac Cardiovasc Surg. 1994;107(1):248-256.
14. Gimpel JA, Lahpor JR, van der Molen AJ, Damen J, 
Hitchcock JF. Reduction of reperfusion injury of human 
myocardium by allopurinol: a clinical study. Free Radic 
Biol Med. 1995;19(2):251-255.
15. Castelli P, Condemi AM, Brambillasca C, Fundaro P, Bot-
ta M, Lemma M, Vanelli P, et al. Improvement of cardiac 
function by allopurinol in patients undergoing cardiac 
surgery. J Cardiovasc Pharmacol. 1995;25(1):119-125.
16. Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, 
Lau J, Carpenter J, et al. Recommendations for examining 
and interpreting funnel plot asymmetry in meta-analyses 
of randomised controlled trials. BMJ. 2011;343:d4002.
